Clinical Trial Update: Alnuctamab for Refractory SLE (LATTE Study) [Phase 1]

View source ↗

Summary

A Phase 1 LATTE study evaluating alnuctamab for refractory systemic lupus erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Alnuctamab

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING